Vistagen Therapeutics, Inc. (VTGN)

NASDAQ: VTGN · Real-Time Price · USD

Compare

0.5300

+0.0244 (4.83%)

At close: Feb 17, 2026, 4:00 PM EST

0.5292

-0.0008 (-0.15%)

Pre-market: Feb 18, 2026, 4:00 AM EST

Vistagen Therapeutics Income Statement

Financials in millions USD. Fiscal year is April - March.

Millions USD. Fiscal year is Apr - Mar.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec '25 Dec 31, 2025	Mar '25 Mar 31, 2025	Mar '24 Mar 31, 2024	Mar '23 Mar 31, 2023	Mar '22 Mar 31, 2022	Mar '21 Mar 31, 2021
Revenue	0.79	0.49	1.06	-0.23	1.11	1.09
Revenue Growth (YoY)	13.04%	-54.32%	-	-	1.78%	-
Gross Profit	0.79	0.49	1.06	-0.23	1.11	1.09
Selling, General & Admin	18.57	17.08	14.06	14.66	13.96	7.64
Research & Development	52.12	39.38	20.02	44.38	34.92	11.38
Operating Expenses	70.69	56.46	34.09	59.04	48.89	19.02
Operating Income	-69.9	-55.97	-33.02	-59.27	-47.78	-17.93
Interest Expense	-	-	-	-	-	-0.01
Interest & Investment Income	2.84	4.56	3.35	0.03	0.02	0.02
Other Non Operating Income (Expenses)	0.01	0.01	0.31	-	-	0
EBT Excluding Unusual Items	-67.05	-51.41	-29.36	-59.24	-47.76	-17.93
Pretax Income	-67.05	-51.41	-29.36	-59.24	-47.76	-17.93
Income Tax Expense	-	0.01	0	0.01	0	0
Net Income	-67.05	-51.42	-29.36	-59.25	-47.76	-17.93
Preferred Dividends & Other Adjustments	-	-	-	-	0.95	24.39
Net Income to Common	-67.05	-51.42	-29.36	-59.25	-48.71	-42.32
Shares Outstanding (Basic)	35	31	19	7	7	3
Shares Outstanding (Diluted)	35	31	19	7	7	3
Shares Change (YoY)	15.56%	59.53%	178.13%	5.45%	129.85%	96.34%
EPS (Basic)	-1.89	-1.67	-1.52	-8.51	-7.38	-14.74
EPS (Diluted)	-1.89	-1.67	-1.52	-8.51	-7.38	-14.74
Free Cash Flow	-60.54	-42.29	-25.87	-49.93	-45.46	-12.35
Free Cash Flow Per Share	-1.71	-1.37	-1.34	-7.17	-6.89	-4.30
Gross Margin	100.00%	100.00%	100.00%	-	100.00%	100.00%
Operating Margin	-8859.82%	-11517.08%	-3103.48%	-	-4308.68%	-1646.06%
Profit Margin	-8497.59%	-10579.83%	-2759.59%	-	-4392.42%	-3884.33%
Free Cash Flow Margin	-7672.62%	-8701.24%	-2431.77%	-	-4099.28%	-1133.45%
EBITDA	-69.72	-55.82	-32.89	-59.14	-47.63	-17.82
D&A For EBITDA	0.19	0.15	0.13	0.13	0.15	0.12
EBIT	-69.9	-55.97	-33.02	-59.27	-47.78	-17.93
Revenue as Reported	0.79	0.49	1.06	-0.23	1.11	1.09

Updated Dec 31, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q